A multimodal nano agent for image-guided cancer surgery

Biomaterials

Volumn 67, Issue , 2015, Pages 160-168

  Zheng, Jinzi ^a,b,f   Muhanna, Nidal ^b,c   De Souza, Raquel ^b,d   Wada, Hironobu ^c,e   Chan, Harley ^a,b   Akens, Margarete K ^a,c   Anayama, Takashi ^c,e   Yasufuku, Kazuhiro ^a,c,e,f   Serra, Stefano ^e   Irish, Jonathan ^a,b,c   Allen, Christine ^d   Jaffray, David ^a,b,d,f  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e TORONTO GENERAL HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Computed tomography; Image guided surgery; Liposomes; Multimodality imaging; Nearinfrared fluorescence

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DISEASES; IMAGE ENHANCEMENT; INFRARED DEVICES; LIPOSOMES; PATIENT REHABILITATION; SURGERY; VISUALIZATION;

ANIMAL MODELS OF CANCER; CANCER; FLUORESCENCE OPTICAL IMAGING; IMAGE GUIDED SURGERY; INTRA-OPERATIVE IMAGING; MULTI-MODALITY IMAGING; NEAR-INFRARED FLUORESCENCE; TUMOR TO BACKGROUND RATIOS;

FLUORESCENCE IMAGING;

INDOCYANINE GREEN; IOHEXOL; LIPOSOME; NANO LIPOSOMAL AGENT; NANOCARRIER; UNCLASSIFIED DRUG; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST METASTASIS; CANCER SURGERY; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; EX VIVO STUDY; FEMALE; FLUORESCENCE IMAGING; IMAGE ANALYSIS; IMAGE GUIDED CANCER SURGERY; IMAGING SOFTWARE; IN VIVO STUDY; INTRAOPERATIVE PERIOD; LIPOSOMAL DELIVERY; LYMPH NODE METASTASIS; LYMPHOGRAPHY; MOUSE; MULTIMODAL IMAGING; NANOENCAPSULATION; NEAR INFRARED FLUORESCENCE IMAGING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; THREE DIMENSIONAL IMAGING; TUMOR VOLUME; ANIMAL; BREAST TUMOR; CHEMISTRY; COMPUTER ASSISTED SURGERY; DISEASE MODEL; FLUORESCENCE; HUMAN; NEOPLASMS; OVARY TUMOR; PATHOLOGY; RABBIT; RADIOGRAPHY; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENCE; HUMANS; LIPOSOMES; MICE, SCID; MULTIMODAL IMAGING; NANOPARTICLES; NEOPLASMS; OVARIAN NEOPLASMS; RABBITS; SURGERY, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84939612971     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.07.010     Document Type: Article

References (43)

1. Hayat M.J., Howlader N., Reichman M.E., Edwards B.K. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2007, 12:20-37.
2. Bilimoria K.Y., Bentrem D.J., Ko C.Y., Stewart A.K., Winchester D.P., Talamonti M.S., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann. Surg. 2007, 246:375-381. (discussion 81-4).
3. Chang M.Y., Mentzer S.J., Colson Y.L., Linden P.A., Jaklitsch M.T., Lipsitz S.R., et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 2007, 134:850-856.
4. Shin D., Park S.S. Clinical importance and surgical decision-making regarding proximal resection margin for gastric cancer. World J. Gastrointest. Oncol. 2013, 5:4-11.
5. Kenngott H.G., Wagner M., Gondan M., Nickel F., Nolden M., Fetzer A., et al. Real-time image guidance in laparoscopic liver surgery: first clinical experience with a guidance system based on intraoperative CT imaging. Surg. Endosc. 2014 Mar, 28(3):933-940.
6. King E., Daly M.J., Chan H., Bachar G., Dixon B.J., Siewerdsen J.H., et al. Intraoperative cone-beam CT for head and neck surgery: feasibility of clinical implementation using a prototype mobile C-arm. Head Neck 2013 Jul, 35(7):959-967.
7. Nguyen Q.T., Tsien R.Y. Fluorescence-guided surgery with live molecular navigation - a new cutting edge. Nat. Rev. Cancer 2013, 13:653-662.
8. Stummer W., Novotny A., Stepp H., Goetz C., Bise K., Reulen H.J. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J. Neurosurg. 2000, 93:1003-1013.
9. van Dam G.M., Themelis G., Crane L.M., Harlaar N.J., Pleijhuis R.G., Kelder W., et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat. Med. 2011, 17:1315-1319.
10. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N. Engl. J. Med. 2011, 365:395-409.
11. Suzuki K., Nagai K., Yoshida J., Ohmatsu H., Takahashi K., Nishimura M., et al. Video-assisted thoracoscopic surgery for small indeterminate pulmonary nodules: indications for preoperative marking. Chest 1999, 115:563-568.
12. Heath C.H., Deep N.L., Sweeny L., Zinn K.R., Rosenthal E.L. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model. Ann. Surg. Oncol. 2012, 19:3879-3887.
13. Nguyen Q.T., Olson E.S., Aguilera T.A., Jiang T., Scadeng M., Ellies L.G., et al. Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:4317-4322.
14. Choi H.S., Gibbs S.L., Lee J.H., Kim S.H., Ashitate Y., Liu F., et al. Targeted zwitterionic near-infrared fluorophores for improved optical imaging. Nat. Biotechnol. 2013, 31:148-153.
15. Marshall M.V., Draney D., Sevick-Muraca E.M., Olive D.M. Single-dose intravenous toxicity study of IRDye 800CW in Sprague-Dawley rats. Mol. Imaging Biol. 2010, 12:583-594.
16. Bradbury M.S., Phillips E., Montero P.H., Cheal S.M., Stambuk H., Durack J.C., et al. Clinically-translated silica nanoparticles as dual-modality cancer-targeted probes for image-guided surgery and interventions. Integr. Biol. (Camb.) 2012, 5:74-86.
17. Schaafsma B.E., Verbeek F.P., Rietbergen D.D., van der Hiel B., van der Vorst J.R., Liefers G.J., et al. Clinical trial of combined radio- and fluorescence-guided sentinel lymph node biopsy in breast cancer. Br. J. Surg. 2013, 100:1037-1044.
18. van der Poel H.G., Buckle T., Brouwer O.R., Valdes Olmos R.A., van Leeuwen F.W. Intraoperative laparoscopic fluorescence guidance to the sentinel lymph node in prostate cancer patients: clinical proof of concept of an integrated functional imaging approach using a multimodal tracer. Eur. Urol. 2011, 60:826-833.
19. Schaafsma B.E., van der Vorst J.R., Gaarenstroom K.N., Peters A.A., Verbeek F.P., de Kroon C.D., et al. Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. Gynecol. Oncol. 2012, 127:126-130.
20. Schaafsma B.E., Mieog J.S., Hutteman M., van der Vorst J.R., Kuppen P.J., Lowik C.W., et al. The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery. J. Surg. Oncol. 2011, 104:323-332.
21. Phillips E., Penate-Medina O., Zanzonico P.B., Carvajal R.D., Mohan P., Ye Y., et al. Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe. Sci. Transl. Med. 2014, 6:260ra149.
22. Zheng J., Liu J., Dunne M., Jaffray D.A., Allen C. In vivo performance of a liposomal vascular contrast agent for CT and MR-based image guidance applications. Pharm. Res. 2007, 24:1193-1201.
23. Zheng J., Perkins G., Kirilova A., Allen C., Jaffray D.A. Multimodal contrast agent for combined computed tomography and magnetic resonance imaging applications. Invest. Radiol. 2006, 41:339-348.
24. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006, 66:3386-3391.
25. Lin L.M., Chen Y.K., Chen C.H., Chen Y.W., Huang A.H., Wang W.C. VX2-induced rabbit buccal carcinoma: a potential cancer model for human buccal mucosa squamous cell carcinoma. Oral Oncol. 2009, 45:e196-203.
26. Anayama T., Nakajima T., Dunne M., Zheng J., Allen C., Driscoll B., et al. A novel minimally invasive technique to create a rabbit VX2 lung tumor model for nano-sized image contrast and interventional studies. PLoS One 2013, 8:e67355.
27. Granton P.V., Norley C.J., Umoh J., Turley E.A., Frier B.C., Noble E.G., et al. Rapid in vivo whole body composition of rats using cone beam uCT. J. Appl. Physiol. 2010, 109:1162-1169.
28. Patchen M.L., MacVittie T.J., Souza L.M. Postirradiation treatment with granulocyte colony-stimulating factor and preirradiation WR-2721 administration synergize to enhance hemopoietic reconstitution and increase survival. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22:773-779.
29. Zheng J., Jaffray D., Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. Mol. Pharm. 2009, 6:571-580.
30. Zheng J., Jaffray D.A., Allen C. Nanosystems for multimodality in vivo imaging. Multifunctional Pharmaceutical Nanocarriers 2008, 409-430. Springer Science + Business Media, LLC. V.P. Torchilin (Ed.).
31. Reuthebuch O., Haussler A., Genoni M., Tavakoli R., Odavic D., Kadner A., et al. Novadaq SPY: intraoperative quality assessment in off-pump coronary artery bypass grafting. Chest 2004, 125:418-424.
32. Vogt P.R., Bauer E.P., Graves K. Novadaq spy intraoperative imaging system - current status. Thorac. Cardiovasc. Surg. 2003, 51:49-51.
33. Zheng J., Allen C., Serra S., Vines D., Charron M., Jaffray D.A. Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology. Contrast Media Mol. Imaging 2010, 5:147-154.
34. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carr. Syst. 1989, 6:193-210.
35. Zheng M., Yue C., Ma Y., Gong P., Zhao P., Zheng C., et al. Single-step assembly of DOX/ICG loaded lipid-polymer nanoparticles for highly effective chemo-photothermal combination therapy. ACS Nano 2013, 7:2056-2067.
36. Proulx S.T., Luciani P., Derzsi S., Rinderknecht M., Mumprecht V., Leroux J.C., et al. Quantitative imaging of lymphatic function with liposomal indocyanine green. Cancer Res. 2010, 70:7053-7062.
37. Tawfik A.M., Razek A.A., Kerl J.M., Nour-Eldin N.E., Bauer R., Vogl T.J. Comparison of dual-energy CT-derived iodine content and iodine overlay of normal, inflammatory and metastatic squamous cell carcinoma cervical lymph nodes. Eur. Radiol. 2014 Mar, 24(3):574-580.
38. Tang C.X., Zhang L.J., Han Z.H., Zhou C.S., Krazinski A.W., Silverman J.R., et al. Dual-energy CT based vascular iodine analysis improves sensitivity for peripheral pulmonary artery thrombus detection: an experimental study in canines. Eur. J. Radiol. 2013 Dec, 82(12):2270-2278.
39. Chandarana H., Megibow A.J., Cohen B.A., Srinivasan R., Kim D., Leidecker C., et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. AJR Am. J. Roentgenol. 2011, 196:W693-W700.
40. Tran D.N., Straka M., Roos J.E., Napel S., Fleischmann D. Dual-energy CT discrimination of iodine and calcium: experimental results and implications for lower extremity CT angiography. Acad. Radiol. 2009, 16:160-171.
41. Sommer C.M., Schwarzwaelder C.B., Stiller W., Schindera S.T., Stampfl U., Bellemann N., et al. Iodine removal in intravenous dual-energy CT-cholangiography: is virtual non-enhanced imaging effective to replace true non-enhanced imaging?. Eur. J. Radiol. 2011, 81:692-699.
42. Kulkarni N.M., Pinho D.F., Kambadakone A.R., Sahani D.V. Emerging technologies in CT-radiation dose reduction and dual-energy CT. Semin. Roentgenol. 2013, 48:192-202.
43. Guided Therapeutics Operating Room. Toronto; 2013. http://technainstitute.com/resources-places/gtxor/.